All In MedTech

Device Trial Radar · NCT07802119

Transjugular Approach for Implantation of Active Fixation Leadless Pacemakers

Transjugular Approach for Implantation of Active Fixation Leadless Pacemakers: A Feasibility Study

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Oct 10, 2026

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Min ShenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 3, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, single-arm, single-center feasibility study evaluating the safety and feasibility of transjugular (internal jugular vein) implantation of the Aveir VR leadless ventricular pacemaker in patients requiring ventricular pacing. A total of 15 patients will be enrolled at Xijing Hospital. The primary objective is to assess procedural feasibility and acute safety (from intraoperative to 48 hours post-procedure). Secondary objectives include short-term (1 to 3 months) pacing parameter stability (threshold, R-wave amplitude, impedance), technical success rate, procedure-related metrics, and adverse event rates.

Conditions

  • Bradycardia
  • Heart Block
  • Sick Sinus Syndrome
  • Atrioventricular Block

Interventions

  • Aveir VR Leadless PacemakerDevice

    The Aveir VR leadless pacemaker is implanted via a transjugular (jugular vein) approach. This active-fixation device is placed in the right ventricle for ventricular pacing indications.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Participants with Sustained Successful Aveir VR Lead Implantation (evaluated by fluoroscopy and clinical-electrophysiological follow-up)Time frame: Through 3 months post-procedure
  2. Acute adverse event rateTime frame: Periprocedural and up to 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xijing Hospital, The First Affiliated Hospital of Air Force Medical University

    Xi'an, Shaanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.